oxymetazoline has been researched along with Hypertension in 10 studies
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the first 3 h after administration of PPA, there was a dose-response increase in the systolic and diastolic blood pressures, which then returned to baseline." | 2.69 | Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. ( Graf, P; Hallén, H; Palm, J; Toll, K, 1999) |
| " Given its vasoconstrictive properties, it can have cardiovascular adverse effects when systemically absorbed." | 1.62 | Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use. ( Cartabuke, R; Jatana, KR; Tobias, JD, 2021) |
| "Oxymetazoline nasal spray is a potent alpha 1-adrenergic agonist commonly used to vasoconstrict blood vessels in the nasal mucosa." | 1.29 | Cardiac arrest after oxymetazoline nasal spray. ( Thrush, DN, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cartabuke, R | 1 |
| Tobias, JD | 1 |
| Jatana, KR | 1 |
| Bellew, SD | 1 |
| Johnson, KL | 1 |
| Nichols, MD | 1 |
| Kummer, T | 1 |
| Latham, GJ | 1 |
| Jardine, DS | 1 |
| Schechtman, SA | 1 |
| Wertz, AP | 1 |
| Shanks, A | 1 |
| Thompson, A | 1 |
| Tremper, K | 1 |
| Pynnonen, MA | 1 |
| Healy, DW | 1 |
| Thrush, DN | 1 |
| Le Jossec, M | 1 |
| Cloix, JF | 1 |
| Dausse, JP | 1 |
| Sprung, J | 1 |
| Alhaddad, ST | 1 |
| Graf, P | 1 |
| Toll, K | 1 |
| Palm, J | 1 |
| Hallén, H | 1 |
| Remie, R | 1 |
| Van Rossum, JX | 1 |
| Coppes, RP | 1 |
| Zaagsma, J | 1 |
| Schmitt, H | 1 |
| Fénard, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.[NCT02285634] | 68 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in diastolic blood pressure. (NCT02285634)
Timeframe: baseline, 30 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Oxymetazoline 0.05% | 5.7 |
| Phenylephrine 0.25% | 7.9 |
| Lidocaine 1% Plus Epinephrine 1:100,000 | 6.2 |
| Bacteriostatic 0.9% NaCL | 9.3 |
Change from baseline in heart rate. (NCT02285634)
Timeframe: baseline, 30 minutes
| Intervention | beats/min (Mean) |
|---|---|
| Oxymetazoline 0.05% | 2.8 |
| Phenylephrine 0.25% | 5.2 |
| Lidocaine 1% Plus Epinephrine 1:100,000 | 7.5 |
| Bacteriostatic 0.9% NaCL | 6.8 |
Change in mean arterial blood pressure from the baseline measurement (NCT02285634)
Timeframe: baseline, 30 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Oxymetazoline 0.05% | 5.1 |
| Phenylephrine 0.25% | 6.4 |
| Lidocaine 1% Plus Epinephrine 1:100,000 | 4.6 |
| Bacteriostatic 0.9% NaCL | 6.5 |
Change from baseline in systolic blood pressure. (NCT02285634)
Timeframe: baseline, 30 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Oxymetazoline 0.05% | 7.5 |
| Phenylephrine 0.25% | 8.2 |
| Lidocaine 1% Plus Epinephrine 1:100,000 | 3.5 |
| Bacteriostatic 0.9% NaCL | 8.9 |
2 trials available for oxymetazoline and Hypertension
| Article | Year |
|---|---|
Effect of Intranasal Vasoconstrictors on Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Intranasal; Anesthetics, Local; Blood Pressure; Double-Blind Method; Emergency Servi | 2018 |
Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aerosols; Blood Pressure; Cross-Over Studie | 1999 |
8 other studies available for oxymetazoline and Hypertension
| Article | Year |
|---|---|
Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use.
Topics: Age Factors; Child; Child, Preschool; Female; Heart Rate; Humans; Hypertension; Intraoperative Compl | 2021 |
Oxymetazoline and hypertensive crisis in a child: can we prevent it?
Topics: Administration, Inhalation; Administration, Intranasal; Blood Pressure; Child; Child, Preschool; Dru | 2013 |
Preoperative β-blockade and hypertension in the first hour of functional endoscopic sinus surgery.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Anesthetics, Local; Chronic Disease; Dr | 2017 |
Cardiac arrest after oxymetazoline nasal spray.
Topics: Anti-Arrhythmia Agents; Atropine; Bradycardia; Cardiopulmonary Resuscitation; Child, Preschool; Endo | 1995 |
[Evidence for two alpha 2B-adrenoreceptor isoforms in the renal cortex of salt-sensitive and salt resistant Sabra rats. Effect of salt loading].
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Guanabenz; Hyp | 1995 |
Use of anticholinergics to treat bradycardia caused by alpha1-adrenergic agonist overdose is not safe.
Topics: Administration, Inhalation; Adrenergic alpha-Agonists; Bradycardia; Child, Preschool; Cholinergic An | 1996 |
Dysfunctional presynaptic alpha 2-adrenoceptors expose facilitatory beta 2-adrenoceptors in the vasculature of spontaneously hypertensive rats.
Topics: Animals; Cocaine; Fenoterol; Hypertension; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Nore | 1992 |
[Effect of sympathomimetics on the vasomotor centers].
Topics: Animals; Blood Pressure; Bradycardia; Cats; Hemodynamics; Hypertension; Hypotension; Isoproterenol; | 1971 |